Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Glendale, CA
NPI: 1730262122Primary Practice Location
GLENDALE ADVENTIST MEDICAL CENTER DP/SNF
1509 WILSON TER, Glendale, CA
Primary Employer
Comprehensive Hematology Oncology Centers Inc
adventisthealth.org
HQ Phone
Get M.D. Mihran's Phone Numberphone_androidMobile
Get M.D. Mihran's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1991 - 2027
TX State Medical License
1988 - 2001
IL State Medical License
1984 - 1990
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Medical Oncology
University of Texas Health Science Center at Houston/M D Anderson Cancer Center
Fellowship • Hematology and Medical Oncology
1986 - 1989
Cook County Health and Hospitals System
Residency • Internal Medicine
1983 - 1986
OHSU School of Medicine
ohsu.edu
Medical School
Until 1980
Cairo University School of Medicine
Medical School
Until 1979
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 36415Insertion of needle into vein for collection of blood sample | 670 | 3,769 |
| 2 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 669 | 3,731 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 588 | 1,811 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 292 | 471 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 209 | 1,137 |
Phase II study of carboplatin and continuous infusion bleomycin followed by
Authors: Huber, M H, Lippman, S M, Benner, S E, Shirinian, M, Dimery, I W, Earley, C L, Winn, R J, Brooks, J, Baez, L, Hong, W K
Journal: Ann Oncol
Authors: Joshua Ellenhorn, Moshe Barnajian, Avo Artinyan, Yosef Nasseri, Jason Cohen, Natalie Seiser
Journal: Int J Colorectal Dis
Publication Date: 2024-01-08
A phase II study of ifosfamide in recurrent squamous cell carcinoma of the
Authors: Huber, M H, Lippman, S M, Benner, S E, Shirinian, M, Dimery, I W, Dunnington, J S, Hong, W K
Journal: Am J Clin Oncol
Lead Sponsor: ImmunityBio, Inc.
Intervention / Treatment: DRUG: N-803 + Pembrolizumab, DRUG: N-803 + Nivolumab, DRUG: N-803 + Atezolizumab, DRUG: N-803 + Avelumab, DRUG: N-803 + Durvalumab, DRUG: N-803 + Pembrolizumab + PD-L1 t-haNK, DRUG: N-803 + Nivolumab + PD-L1 t-haNK, DRUG: N-803 + Atezolizumab + PD-L1 t-haNK, DRUG: N-803 + Avelumab + PD-L1 t-haNK, DRUG: N-803 + Durvalumab + PD-L1 t-haNK, DRUG: N-803 + Docetaxel + Pembrolizumab, DRUG: N-803 + Docetaxel + Nivolumab
Lead Sponsor: Stemline Therapeutics, Inc.
Intervention / Treatment: DRUG: Standard of Care, DRUG: Elacestrant
Lead Sponsor: ImmunityBio, Inc.
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab, DRUG: N-803 + Pembrolizumab, DRUG: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab, DRUG: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed, DRUG: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab, DRUG: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
